Mark Cuban Sounds Alarm on Drug Costs: “We Need to Reevaluate Everything”
Table of Contents
The soaring cost of cutting-edge cell and gene therapies is pushing the American healthcare system to its breaking point, according to entrepreneur Mark Cuban, who recently shared his concerns on the STAT News’s Readout Loud podcast. Cuban revealed he personally funded $1.8 million in therapy for twins suffering from a genetic disease, a burden he believes is unsustainable for most families and a symptom of a deeply flawed system.
The $1.8 Million Question & A Novel Proposal
Cuban’s personal experience underscores the financial toxicity of these advanced treatments. He described a potential solution inspired by cord blood banking – a service where families pay a recurring fee to preserve their newborn’s cord blood, despite a low probability of ever needing it. “I have three kids and we got…the cord blood thing for all of them, where you save the cord blood and pay X amount a year, but there’s a 99% chance you’re never going to use it,” Cuban explained. He proposes applying a similar model to expensive therapies, offering families access for a nominal annual fee – “a dollar a year per child, or $50 or $100 one time” – with funds held in escrow to ensure accessibility should the need arise.
While acknowledging the idea was a “throwaway” thought, Cuban emphasized the need for a fundamental reassessment of healthcare financing. He believes the current insurance system is ill-equipped to handle the financial strain of these new therapies. Diabetes and immunology drugs is expected to slow. Obesity treatments, though slowing in growth, will still represent a meaningful cost. IQVIA Global Use of Medicines Outlook Through 2029
This shift away from procedural costs towards therapeutic costs has significant implications for insurance. If the primary expense becomes lifelong therapy or a considerable one-time fee, insurance premiums are likely to become “even more prohibitively expensive.”
Potential Solutions & The Road Ahead
Cuban outlined several potential pathways forward, each with its own challenges:
- Government Intervention: Leveraging federal research funding – which often contributes to drug advancement – to negotiate lower prices. While acknowledging the need to incentivize pharmaceutical innovation, Cuban questioned whether “blockbuster profits at the expense of patients in perpetuity” are justifiable.
- Insurance & PBM Reform: Addressing the role of Pharmacy Benefit Managers (PBMs) in determining drug coverage. A recent case highlighted the difficulties patients face when insurers exclude life-saving drugs from their formulary, as reported by The New York times in 2023. One patient,Scott Matsuda,faced a $6,000 monthly cost for a drug that dramatically improved his condition after his insurer removed it from coverage. The Federal Trade Commission (FTC) has also scrutinized rebate practices between manufacturers and PBMs,citing potential illegal bribery. Reinsurance programs, as proposed by Cuban, could provide a safety net for insurers, but some existing plans exclude cell and gene therapies.
- Insurance Reinvention: A complete overhaul of the insurance system, perhaps involving universal coverage and dramatically increased premiums. This could necessitate stricter prior authorizations, particularly for therapies administered to young children who have not yet contributed to the system.
- Reliance on Crowdfunding: A grim scenario where patients increasingly rely on platforms like GoFundMe, leaving many without access to life-saving treatments.
Ultimately, this new era of therapeutics challenges fundamental assumptions about healthcare – the value of prevention, the effectiveness of value-based care, and even the viability of the current insurance model. While extensive health reform remains uncertain, Cuban’s warning serves as a stark reminder that the status quo is unsustainable and that a reckoning is on the horizon. It will likely, at the very least, increase premiums for now.
